Technology

Cyclerion Therapeutics

$3.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.49%) As of 2:56 PM UTC today

Why Robinhood?

You can buy or sell CYCN and other stocks, options, and ETFs commission-free!

About CYCN

Cyclerion Therapeutics, Inc. Common Stock, also called Cyclerion Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA. The listed name for CYCN is Cyclerion Therapeutics, Inc. Common Stock.

CEO
Peter M. Hecht
Employees
94
Headquarters
Cambridge, Massachusetts
Founded
2018
Market Cap
113.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
296.18K
High Today
$3.40
Low Today
$3.33
Open Price
$3.35
Volume
17.20K
52 Week High
$8.96
52 Week Low
$2.08

Collections

CYCN Earnings

-$1.18
-$0.79
-$0.39
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

OCSL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure